Latest news with #Adia
Yahoo
16-05-2025
- Business
- Yahoo
CORRECTION FROM SOURCE: Adia Nutrition Inc. Successfully Uplists to OTCQB Venture Market in Record-Breaking Six Weeks and Completes SEC Rule 15c2-11 Compliance
This release corrects and replaces the press release issued by Adia Nutrition Inc., on May 16, 2025, at 8:09 am EDT. Winter Park, Florida--(Newsfile Corp. - May 16, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces its successful uplisting from the OTC Pink Sheets to the OTCQB Venture Market, effective today. This milestone, achieved in an unprecedented six weeks from the filing date of April 2nd, 2025, alongside the completion of SEC Rule 15c2-11 compliance, reinforces Adia's commitment to transparency, investor accessibility, and delivering on its promises with remarkable speed. OTCQB Uplisting To view an enhanced version of this graphic, please visit: The OTCQB uplisting process, which typically takes companies an average of 12-16 weeks from filing to approval, was executed by Adia Nutrition with exceptional efficiency. This rapid timeline-less than half the industry norm-demonstrates the company's operational excellence and close collaboration with OTC Markets Group, following an independent audit with Astra Audit and Advisory LLC on April 1, 2025. The completion of SEC Rule 15c2-11 compliance is a pivotal achievement, ensuring Adia's financial information is publicly available and meets stringent transparency standards. This rule requires broker-dealers to review and maintain current issuer information before quoting securities, enhancing investor confidence and enabling broader market participation. By satisfying 15c2-11, Adia Nutrition strengthens its credibility, facilitates trading liquidity, and positions itself as a trusted investment opportunity in the regenerative medicine sector. "Uplisting to OTCQB in six weeks and completing 15c2-11 compliance reflect our relentless focus on execution and transparency," said Larry Powalisz, CEO of Adia Nutrition Inc. "We promised our shareholders enhanced visibility, liquidity, and trust, and we've delivered-faster than most. This is yet another goal we set and achieved swiftly, paving the way for our continued growth and our ultimate vision of a Nasdaq Small Cap listing." The OTCQB Venture Market and 15c2-11 compliance elevate Adia Nutrition's ability to showcase its pioneering umbilical cord stem cell therapies and premium nutritional products to a wider investor base. This uplisting follows a series of rapid accomplishments, including the removal of the shell risk designation and the opening of its first Florida clinic for regenerative therapies, solidifying Adia's track record of setting ambitious targets and surpassing them. Adia Nutrition remains dedicated to revolutionizing healthcare through its medical division, specializing in umbilical cord stem cell (UCB-SC) therapies, and its supplement division, delivering premium, organic products. The company invites investors and stakeholders to join its journey as it expands its clinic network and drives innovation. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. (OTCQB: ADIA) is a publicly traded company dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
CORRECTION FROM SOURCE: Adia Nutrition Inc. Successfully Uplists to OTCQB Venture Market in Record-Breaking Six Weeks and Completes SEC Rule 15c2-11 Compliance
This release corrects and replaces the press release issued by Adia Nutrition Inc., on May 16, 2025, at 8:09 am EDT. Winter Park, Florida--(Newsfile Corp. - May 16, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces its successful uplisting from the OTC Pink Sheets to the OTCQB Venture Market, effective today. This milestone, achieved in an unprecedented six weeks from the filing date of April 2nd, 2025, alongside the completion of SEC Rule 15c2-11 compliance, reinforces Adia's commitment to transparency, investor accessibility, and delivering on its promises with remarkable speed. OTCQB Uplisting To view an enhanced version of this graphic, please visit: The OTCQB uplisting process, which typically takes companies an average of 12-16 weeks from filing to approval, was executed by Adia Nutrition with exceptional efficiency. This rapid timeline-less than half the industry norm-demonstrates the company's operational excellence and close collaboration with OTC Markets Group, following an independent audit with Astra Audit and Advisory LLC on April 1, 2025. The completion of SEC Rule 15c2-11 compliance is a pivotal achievement, ensuring Adia's financial information is publicly available and meets stringent transparency standards. This rule requires broker-dealers to review and maintain current issuer information before quoting securities, enhancing investor confidence and enabling broader market participation. By satisfying 15c2-11, Adia Nutrition strengthens its credibility, facilitates trading liquidity, and positions itself as a trusted investment opportunity in the regenerative medicine sector. "Uplisting to OTCQB in six weeks and completing 15c2-11 compliance reflect our relentless focus on execution and transparency," said Larry Powalisz, CEO of Adia Nutrition Inc. "We promised our shareholders enhanced visibility, liquidity, and trust, and we've delivered-faster than most. This is yet another goal we set and achieved swiftly, paving the way for our continued growth and our ultimate vision of a Nasdaq Small Cap listing." The OTCQB Venture Market and 15c2-11 compliance elevate Adia Nutrition's ability to showcase its pioneering umbilical cord stem cell therapies and premium nutritional products to a wider investor base. This uplisting follows a series of rapid accomplishments, including the removal of the shell risk designation and the opening of its first Florida clinic for regenerative therapies, solidifying Adia's track record of setting ambitious targets and surpassing them. Adia Nutrition remains dedicated to revolutionizing healthcare through its medical division, specializing in umbilical cord stem cell (UCB-SC) therapies, and its supplement division, delivering premium, organic products. The company invites investors and stakeholders to join its journey as it expands its clinic network and drives innovation. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. (OTCQB: ADIA) is a publicly traded company dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Black America Web
22-04-2025
- Entertainment
- Black America Web
MFT: Adia Remembers Her First Time Falling On Stage
Black America Web Featured Video CLOSE Erika Goldring For those who believe in His word, it will always be understood that God makes things happen with perfect timing. Take rising Christian R&B singer Adia for example. Even though she released her first and only album to-date over a decade ago, it's the work she's done in recent years alongside the Stellar Award's current 'Album Of The Year' reigning champ, Pastor Mike Jr., and in her own relaunched solo efforts that show just how talented she truly is. RELATED: My First Time : When Ne-Yo Met Beyoncé In a special segment of 'My First Time' that we're sure will garner a few laughs, Adia shares her humbling experience of falling on stage while on the come-up as part of a teenage gospel girl group. Most people would be mortified to get caught slipping while going up the steps, but thankfully our girl used it as the ultimate motivation in understanding how to keep pushing forward when life throws the unexpected your way. Also, it never hurts learning how to laugh at yourself. Watch the latest 'My First Time' below for a slippery story by way of rising contemporary gospel singer Adia: SEE ALSO
Yahoo
14-04-2025
- Business
- Yahoo
Adia Nutrition Inc. Files for OTCQB Uplisting with OTC Markets, Emphasizing OTC-Handled 15c2-11 for Transparency and Investor Reach
Winter Park, Florida--(Newsfile Corp. - April 14, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces that it has officially filed with OTC Markets Group for uplisting to the OTCQB Venture Market. This filing follows the successful completion of an independent audit with Astra Audit and Advisory LLC on April 1, 2025, marking a significant milestone in the company's commitment to enhancing visibility, liquidity, and shareholder value through its innovative stem cell therapies and premium nutritional products. As part of this uplisting process, OTC Markets will handle Adia Nutrition's Form 15c2-11, a critical step under SEC regulations that enables broker-dealers to quote the company's securities. By having OTC Markets facilitate this streamlined review, Adia benefits from a more efficient path to public quotation compared to traditional FINRA filings. This process ensures current financial and operational information is publicly available, boosting transparency and investor confidence. The 15c2-11 completion will also enhance market maker participation, improving trading efficiency, liquidity, and price discovery-key advantages as Adia transitions to the OTCQB's higher reporting standards and broader investor reach. Additionally, Adia Nutrition has requested the Non-Objecting Beneficial Owners (NOBO) list, a strategic move to strengthen shareholder engagement. Obtaining the NOBO list allows the company to directly communicate with street-name shareholders who do not object to sharing their contact details, bypassing intermediaries like brokers. This direct access enhances Adia's ability to share updates on its pioneering work-such as Umbilical Cord Stem Cell (UCB-SC) therapies and Autologous Hematopoietic Stem Cell Transplantation (aHSCT)-while building closer ties with investors and potentially increasing participation in corporate actions like voting or investment opportunities. "We're thrilled to take this next step toward the OTCQB," said Larry Powalisz, CEO of Adia Nutrition Inc. "Filing for uplisting, leveraging OTC Markets for our 15c2-11, and requesting the NOBO list reflect our focus on transparency and growth. These moves not only elevate our market presence but also connect us more directly with the investors who believe in our mission to transform healthcare through stem cell innovation and nutritional excellence." With this filing, Adia Nutrition is poised to capitalize on the OTCQB's benefits, including greater market credibility and access to a wider investor base, as it continues to expand its network of clinics and advance its science-backed solutions. The company remains on track with its broader roadmap toward a potential Nasdaq Small Cap listing, reinforcing its position as a pioneer in regenerative medicine. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
Khaleej Times
03-04-2025
- Business
- Khaleej Times
Adia acquires significant minority stake in French firm
The Abu Dhabi Investment Authority (Adia) has announced its acquisition of a 'significant minority stake' in the French outdoor accommodation firm, the European Camping Group (ECG), through a wholly owned subsidiary. The financial terms of the transaction have not been disclosed. In this deal, PAI Partners, a France-based private equity firm, will sell its minority stake in ECG while retaining majority ownership. The transaction is contingent upon customary regulatory approvals and is expected to be finalized in the second quarter of 2025. PAI Partners first invested in ECG in 2021, focusing on enhancing facilities and amenities across the group's sites and mobile-home fleet. In 2023, PAI expanded its involvement by acquiring VacanceSelect, further integrating European campsite and mobile-home operators into the ECG portfolio. Currently, ECG operates in 11 European countries through its leading brands, Eurocamp and Homair. This strategic investment by Adia aligns with its growing interest in European markets, which now constitute 22 per cent of its portfolio, making it the second-largest region after Asia Pacific, at 38 per cent. Adia, managing nearly $1.06 trillion in assets, has been active in Europe, recently increasing its financial commitment to Cheyne Capital's real estate private credit strategy, targeting senior lending against European real estate. The undisclosed investment raised Cheyne's total commitment to $836 million. Additionally, in June, Adia acted as an anchor investor in Pemberton Asset Management's NAV strategic financing strategy, helping to push the initiative's first close to over $1 billion. Hamad Shahwan Aldhaheri, executive director of the private equities department at Adia, praised ECG for establishing itself as a leading player in the outdoor accommodation sector. 'This investment, alongside a proven partner in PAI, aims to support and accelerate the growth of the business,' he said. Bertrand Monier, a partner at PAI, emphasised ECG's position as a market leader, noting the substantial investment and exceptional management driving its success. 'We are delighted to welcome ADIA as our fellow shareholder for the next stage of growth, sharing our vision for ECG and the opportunities to build on its success,' he stated. ECG CEO Sébastien Manceau expressed enthusiasm about the new partnership: 'We are delighted to welcome Adia as a new investor alongside PAI to support our growth trajectory and continue strengthening our leadership in the European outdoor accommodation market. This new chapter will allow us to pursue our geographic diversification journey and focus on organic and operational levers to achieve our full potential.' As Adia continues to expand its footprint in Europe, this investment in ECG reflects its strategic approach to identifying and supporting high-potential businesses in diverse sectors.
